Preclinical CD123-CAR-T cell studies demonstrated strong anti-leukemia effects [64]; however, these were accompanied by loss of normal hematopoiesis in vivo due to CD123 expression on HSC [65], which may raise concerns about safety and potential hematotoxicities when translated into the clinic (Table 2). Here, IL3RA is linked to leukemia.